SCHOTT Pharma KGaA Future Growth
Future criteria checks 3/6
SCHOTT Pharma KGaA is forecast to grow earnings and revenue by 15% and 11.9% per annum respectively. EPS is expected to grow by 14.7% per annum. Return on equity is forecast to be 20% in 3 years.
Key information
15.0%
Earnings growth rate
14.7%
EPS growth rate
Life Sciences earnings growth | 21.7% |
Revenue growth rate | 11.9% |
Future return on equity | 20.0% |
Analyst coverage | Good |
Last updated | 21 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2026 | 1,263 | 225 | 78 | 282 | 9 |
9/30/2025 | 1,109 | 172 | 30 | 241 | 10 |
9/30/2024 | 977 | 146 | -15 | 214 | 9 |
12/31/2023 | 906 | 158 | 37 | 220 | N/A |
9/30/2023 | 899 | 152 | 6 | 182 | N/A |
6/30/2023 | 873 | 143 | 70 | 215 | N/A |
9/30/2022 | 821 | 125 | 29 | 182 | N/A |
9/30/2021 | 649 | 101 | 34 | 132 | N/A |
9/30/2020 | 584 | 77 | 19 | 104 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1SXP's forecast earnings growth (15% per year) is above the savings rate (1.1%).
Earnings vs Market: 1SXP's earnings (15% per year) are forecast to grow faster than the Austrian market (2.6% per year).
High Growth Earnings: 1SXP's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1SXP's revenue (11.9% per year) is forecast to grow faster than the Austrian market (-2.3% per year).
High Growth Revenue: 1SXP's revenue (11.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1SXP's Return on Equity is forecast to be low in 3 years time (20%).